Response and duration by classification
| . | No. enrolled . | No. of responses . | Duration of CR (mo) . | Duration of PR (mo) . |
|---|---|---|---|---|
| PTCL, unspecified or NOS | 27 | 11 | 3, 3, 12, 13+, 74 | 2, 3, 5, 6, 9, 12 |
| Angioimmunoblastic | 6 | 1 | 23+ | |
| Anaplastic large T-cell, ALK neg | 2 | 2 | 6 | 3 |
| Enteropathy associated T-cell lymphoma | 1 | 1 | 8 | |
| PTCL, u of the skin | 1 | 1 | 17 | |
| CD30 lymphoproliferative disorder | 1 | 1 | 49+ |
| . | No. enrolled . | No. of responses . | Duration of CR (mo) . | Duration of PR (mo) . |
|---|---|---|---|---|
| PTCL, unspecified or NOS | 27 | 11 | 3, 3, 12, 13+, 74 | 2, 3, 5, 6, 9, 12 |
| Angioimmunoblastic | 6 | 1 | 23+ | |
| Anaplastic large T-cell, ALK neg | 2 | 2 | 6 | 3 |
| Enteropathy associated T-cell lymphoma | 1 | 1 | 8 | |
| PTCL, u of the skin | 1 | 1 | 17 | |
| CD30 lymphoproliferative disorder | 1 | 1 | 49+ |